Table 1. Top enriched pathways for sorafenib targets with supporting assay values <= 100 nM.
Targets for the drug sorafenib with supporting assay values < 100 nM were retrieved from the Cancer Targetome and then mapped to pathways. Pathway enrichment analysis was performed using a binomial test and p-values were FDR-corrected for multiple testing. The table was generated by ReactomeFIViz. Only pathways having FDR <= 0.01 are listed here.
| Pathway | Pathway
Size |
Number
of Targets in Pathway |
P-value | FDR | Sorafenib Targets in Pathway |
|---|---|---|---|---|---|
| Signaling by Receptor Tyrosine Kinases | 406 | 10 | 1.14E-08 | 1.07E-06 | FLT1,FLT3,FLT4,KDR,PDGFRB,PDGFRA,BRAF,
MAPK14,KIT,FGFR3 |
| RAF/MAP kinase cascade | 202 | 8 | 1.38E-08 | 1.07E-06 | RET,FLT3,PDGFRB,PDGFRA,BRAF,KIT,RAF1,
FGFR3 |
| MAPK1/MAPK3 signaling | 207 | 8 | 1.66E-08 | 1.07E-06 | RET,FLT3,PDGFRB,PDGFRA,BRAF,KIT,RAF1,
FGFR3 |
| MAPK family signaling cascades | 246 | 8 | 6.28E-08 | 3.01E-06 | RET,FLT3,PDGFRB,PDGFRA,BRAF,KIT,RAF1,
FGFR3 |
| VEGF ligand-receptor interactions | 8 | 3 | 1.04E-06 | 3.33E-05 | FLT1,FLT4,KDR |
| VEGF binds to VEGFR leading to
receptor dimerization |
8 | 3 | 1.04E-06 | 3.33E-05 | FLT1,FLT4,KDR |
| Neurophilin interactions with VEGF and
VEGFR |
4 | 2 | 4.47E-05 | 1.21E-03 | FLT1,KDR |
| PI5P, PP2A and IER3 Regulate PI3K/AKT
Signaling |
90 | 4 | 6.10E-05 | 1.43E-03 | PDGFRB,PDGFRA,KIT,FGFR3 |
| Signaling by VEGF | 94 | 4 | 7.22E-05 | 1.43E-03 | FLT1,FLT4,KDR,MAPK14 |
| Negative regulation of the PI3K/AKT
network |
95 | 4 | 7.52E-05 | 1.43E-03 | PDGFRB,PDGFRA,KIT,FGFR3 |
| Negative feedback regulation of MAPK
pathway |
6 | 2 | 1.00E-04 | 1.71E-03 | BRAF,RAF1 |
| RAF activation | 12 | 2 | 3.98E-04 | 6.36E-03 | BRAF,RAF1 |